Literature DB >> 15143213

Cellular and gene therapy for major histocompatibility complex class II deficiency.

Franck Matheux1, Jean Villard.   

Abstract

Major histocompatibility complex (MHC) class II deficiency is a primary immunodeficiency. Lentiviral vectors are used for gene therapy in a mouse model of this disease. In addition, by a direct genetic correction approach, a diagnostic test to determine which of the four MHC II genes is defective in new MHC II-deficiency patients has been optimized.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15143213     DOI： 10.1152/nips.01462.2003

Source DB:  PubMed          Journal:  News Physiol Sci        ISSN： 0886-1714


  5 in total

1.  Phosphorylation and ubiquitination of degron proximal residues are essential for class II transactivator (CIITA) transactivation and major histocompatibility class II expression.

Authors:  Kavita Purnanda Bhat; Agnieszka Dorota Truax; Susanna Fletcher Greer
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  Major histocompatibility complex class II deficiency in Kuwait: clinical manifestations, immunological findings and molecular profile.

Authors:  Waleed Al-Herz; Osama Alsmadi; Motasem Melhem; Mike Recher; Francesco Frugoni; Luigi D Notarangelo
Journal:  J Clin Immunol       Date:  2012-11-10       Impact factor: 8.317

3.  The class II transactivator (CIITA) is regulated by post-translational modification cross-talk between ERK1/2 phosphorylation, mono-ubiquitination and Lys63 ubiquitination.

Authors:  Julie E Morgan; Ronald L Shanderson; Nathaniel H Boyd; Ercan Cacan; Susanna F Greer
Journal:  Biosci Rep       Date:  2015-06-19       Impact factor: 3.840

Review 4.  Hematopoietic Cell Transplantation for MHC Class II Deficiency.

Authors:  Su Han Lum; Benedicte Neven; Mary A Slatter; Andrew R Gennery
Journal:  Front Pediatr       Date:  2019-12-11       Impact factor: 3.418

5.  Implications of hematopoietic stem cells heterogeneity for gene therapies.

Authors:  Jeremy Epah; Richard Schäfer
Journal:  Gene Ther       Date:  2021-02-15       Impact factor: 5.250
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.